Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biotechnology company pioneering advancements in genome engineering. Leveraging revolutionary CRISPR-Cas9 technology, Caribou specializes in developing innovative cellular engineering solutions. Their technology, which pairs Cas9 with guide RNA to facilitate precise DNA modifications, is being harnessed for sophisticated gene knock-outs and knock-ins. Caribou's tools provide transformative capabilities across various sectors, including biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
At the forefront of biopharmaceutical innovation, Caribou is dedicated to applying its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform to create next-generation genome-edited cell therapies. Their pipeline includes allogeneic CAR-T and CAR-NK cell therapies, aimed at treating patients with hematologic malignancies and solid tumors.
Recent milestones include the FDA's feedback on a Phase 3 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting large B cell lymphoma (LBCL). The ongoing ANTLER Phase 1 trial has shown promising results, with CB-010 receiving Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations. Caribou is also expanding CB-010's potential application to lupus nephritis and extrarenal lupus, with a GALLOP Phase 1 trial planned for late 2024.
Financially, Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2026. Their strategic partnerships, including a collaboration with Pfizer, have bolstered their financial standing.
Caribou continues to push the boundaries of genome editing with its chRDNA technology, significantly improving the precision of genome edits. Their commitment to transforming patient lives through cutting-edge science positions them as a leader in the biotech landscape.
Caribou Biosciences announced the acceptance of an abstract detailing initial clinical data from the ongoing ANTLER Phase 1 trial of CB-010, their lead allogeneic CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). The abstract will be presented at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria, from June 9-12, 2022. CB-010 utilizes advanced CRISPR technology aimed at enhancing antitumor activity.
Caribou Biosciences (CRBU) announced positive preclinical data for its allogeneic CAR-T cell therapy candidate, CB-011, aimed at treating relapsed or refractory multiple myeloma. Data presented at the AACR Annual Meeting show that CB-011 cells are effective against BCMA-positive tumor cells and resist immune rejection. The therapy's unique design includes a proprietary anti-BCMA antibody fragment and an immune cloaking strategy to enhance durability. Caribou plans to submit an IND application in 2022, marking a significant step forward for its CAR-T cell therapy platform.
Caribou Biosciences, Inc. (CRBU) reported significant achievements in 2021, including its successful IPO and the initiation of the ANTLER Phase 1 clinical trial for lead candidate CB-010, aimed at treating r/r B-NHL. The company anticipates submitting an IND application for CB-011 for r/r multiple myeloma in 2022. As of December 31, 2021, Caribou has $413.5 million in cash and securities, supporting its allogeneic CAR-T and CAR-NK pipeline. However, the company reported a net loss of $66.9 million for the year.
Caribou Biosciences (NASDAQ: CRBU) announced preclinical data for its allogeneic anti-BCMA CAR-T cell therapy, CB-011, targeting relapsed or refractory multiple myeloma. The data will be showcased at the AACR Annual Meeting 2022, set for April 8-13, 2022, in New Orleans. CB-011 utilizes Cas12a chRDNA technology to prevent immune rejection, focusing on manufacturing an IND application by 2022. The presentation details include the title, presenter, and time, with registered attendees able to access the content online after April 8. Caribou continues advancing its CRISPR-based therapies.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz will present at two investor conferences in March 2022. The first event is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 10:00 am ET. The second is the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, with a presentation webcast starting at 7:00 am ET. Webcasts will be available on Caribou's website for 30 days post-event. The company focuses on CRISPR genome editing technology to develop precise therapies for serious diseases.
On February 7, 2022, Caribou Biosciences (Nasdaq:CRBU) announced that its CEO, Rachel Haurwitz, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17 at 2:20 pm ET. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event.
Caribou specializes in CRISPR genome editing, utilizing advanced technologies, including chRDNAs, for precise gene modifications aimed at developing innovative therapies for serious diseases.
Caribou Biosciences has appointed Dr. Syed Rizvi as chief medical officer, a role aimed at steering its oncology cell therapy pipeline. Dr. Rizvi brings over 20 years of drug development experience, having previously led clinical strategy for CAR-T therapies like ABECMA and BREYANZI. The company plans to disclose initial data from its ANTLER Phase 1 clinical trial for product candidate CB-010 in 2022, file an IND application for CB-011, and select targets for its CAR-NK cell therapy, CB-020. Dr. Rizvi's leadership is anticipated to enhance Caribou’s development efforts.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that Rachel Haurwitz, Ph.D., President and CEO, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:45 am ET. The presentation will be available via live webcast on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is advancing its CRISPR genome-editing technology, focusing on developing next-generation CAR-T and CAR-NK cell therapies to treat severe diseases.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz will attend investor conferences from November 30 to December 2, 2021. The events include the Piper Sandler 33rd Annual Virtual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference. A fireside chat at the latter is scheduled for December 2, from 4:20 to 4:40 PM ET. Webcasts will be available on Caribou's website for 30 days post-event. Caribou is focused on innovative CRISPR genome editing technologies, particularly using chRDNA for developing advanced therapies.
Caribou Biosciences reported promising advancements in its Q3 2021 financial results, with cash and equivalents of $435.3 million, bolstered by a successful IPO that raised $321.0 million. The company is progressing with its lead candidate, CB-010, in the ANTLER Phase 1 trial for non-Hodgkin lymphoma, aiming to share initial data in 2022. Caribou's proprietary chRDNA technology provides enhanced specificity for genome edits, crucial for developing CAR-T therapies. The firm also welcomed new board members and a chief business officer, enhancing its leadership team.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
What does Caribou Biosciences specialize in?
What is CB-010?
What recent FDA feedback did Caribou receive?
How is Caribou's financial health?
What is chRDNA technology?
What are the applications of Caribou's technology?
What designations has CB-010 received from the FDA?
What is the ANTLER trial?
What is Caribou's collaboration with Pfizer?
What upcoming trials are planned for CB-010?
